Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease

Cameron, F.L., Gerasimidis, K. , Papangelou, A., Missiou, D., Garrick, V., Cardigan, T., Buchanan, E., Barclay, A.R., McGrogan, P. and Russell, R.K. (2013) Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 37(6), pp. 622-629. (doi:10.1111/apt.12230)

Full text not currently available from Enlighten.

Abstract

<p>Background: Exclusive enteral nutrition (EEN) is an effective first line treatment for active paediatric Crohn's disease (CD).</p> <p>Aim: To examine the effect of EEN on short- and long-term clinical outcome together with anthropometric measurements.</p> <p>Methods: Retrospective case-note review in newly diagnosed CD (<16 years) who completed 8 weeks of EEN. Demographics, anthropometry, disease characteristics and inflammatory markers were collected at EEN initiation and at 1, 2, 6, 12 and 24 months post treatment initiation. EEN response was determined by a patient global assessment.</p> <p>Results: One hundred and nine patients were included (Males 68; Median age: 11.2 years). After 8 weeks EEN, 65 were in remission, 32 improved and 12 had no improvement. By 4 weeks, mean weight/BMI z-score (s.d.) increased (P < 0.02) and between 4 and 8 weeks (P < 0.05). Baseline inflammatory markers all improved significantly by week 4 (albumin, CRP and platelets; all P < 0.01) and ESR (P < 0.00001). 63/109(58%) relapsed during follow-up. 44/63(70%) patients completed a second course of EEN with similar response rate, but lower weight gain (3.3 vs. 5.1 kg, P < 0.05). Height z-score did not change significantly over the 24 months. Introduction of azathioprine within 6 months of diagnosis did not improve height outcomes at 24 months.</p> <p>Conclusions: Weight and BMI z-score improved with EEN and changes are sustained to 2 years, but height z-score did not. Seventy per cent of patients who relapsed during 2-year follow-up managed a 2nd course of EEN. The optimal therapeutic strategies for length of EEN course and to improve linear growth are awaited.</p>

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Gerasimidis, Dr Konstantinos
Authors: Cameron, F.L., Gerasimidis, K., Papangelou, A., Missiou, D., Garrick, V., Cardigan, T., Buchanan, E., Barclay, A.R., McGrogan, P., and Russell, R.K.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Alimentary Pharmacology and Therapeutics
Publisher:Wiley-Blackwell Publishing Ltd.
ISSN:0269-2813
ISSN (Online):1365-2036
Published Online:30 January 2013

University Staff: Request a correction | Enlighten Editors: Update this record